The interconnection between lipoprotein(a), lipoprotein(a) cholesterol and true LDL-cholesterol in the diagnosis of familial hypercholesterolemia.
Journal
Current opinion in lipidology
ISSN: 1473-6535
Titre abrégé: Curr Opin Lipidol
Pays: England
ID NLM: 9010000
Informations de publication
Date de publication:
12 2020
12 2020
Historique:
pubmed:
8
10
2020
medline:
16
10
2021
entrez:
7
10
2020
Statut:
ppublish
Résumé
Elevated levels of lipoprotein(a) [Lp(a)] are present in 30-50% of patients with familial hypercholesterolemia. The contribution of Lp(a) towards risk stratification of patients with familial hypercholesterolemia has been recently recognized, with studies showing a significantly worse prognosis if Lp(a) is elevated. However, the role of elevated Lp(a) in diagnosis of familial hypercholesterolemia is less well defined or accepted. An important confounder in the diagnosis of familial hypercholesterolemia is the significant contribution of the cholesterol content on Lp(a) (Lp(a)-C) in individuals with elevated Lp(a). Because Lp(a)-C is incorporated into all clinical LDL-C measurements, it can contribute significantly to the cholesterol threshold diagnostic criteria for familial hypercholesterolemia used in most clinical algorithms. In this review, we discuss the interrelationship of Lp(a), Lp(a)-C and correct LDL-C in the diagnosis and prognosis of familial hypercholesterolemia. Future studies of accurately measuring correct LDL-C or in using apoB-100 and Lp(a) criteria may overcome the limitations of using estimated LDL-C in the diagnosis of familial hypercholesterolemia in individuals with concomitant elevation of Lp(a).
Identifiants
pubmed: 33027223
doi: 10.1097/MOL.0000000000000713
pii: 00041433-202012000-00002
doi:
Substances chimiques
Cholesterol, LDL
0
Lipoprotein(a)
0
Types de publication
Journal Article
Review
Langues
eng
Sous-ensembles de citation
IM
Pagination
305-312Références
McGowan MP, Hosseini Dehkordi SH, Moriarty PM, Duell PB. Diagnosis and treatment of heterozygous familial hypercholesterolemia. J Am Heart Assoc 2019; 8:e013225.
Luirink IK, Wiegman A, Kusters DM, et al. 20-year follow-up of statins in children with familial hypercholesterolemia. N Engl J Med 2019; 381:1547–1556.
Boffa MB, Koschinsky ML. Oxidized phospholipids as a unifying theory for lipoprotein(a) and cardiovascular disease. Nat Rev Cardiol 2019; 16:305–318.
Stiekema LCA, Prange KHM, Hoogeveen RM, et al. Potent lipoprotein(a) lowering following apolipoprotein(a) antisense treatment reduces the pro-inflammatory activation of circulating monocytes in patients with elevated lipoprotein(a). Eur Heart J 2020; 41:2262–2271.
Tsimikas S. A test in context: lipoprotein(a): diagnosis, prognosis, controversies, and emerging therapies. J Am Coll Cardiol 2017; 69:692–711.
Yeang C, Tsimikas S. The role of lipoprotein(a) in calcific AV disease and insights into its medical therapies. https://www.acc.org/latest-in-cardiology/articles/2020/04/27/11/08/the-role-of-lipoproteina-in-calcific-av-disease. 2020. [Accessed date 8 March 2020].
Zheng KH, Tsimikas S, Pawade T, et al. Lipoprotein(a) and oxidized phospholipids promote valve calcification in patients with aortic stenosis. J Am Coll Cardiol 2019; 73:2150–2162.
Yeang C, Witztum JL, Tsimikas S. ’LDL-C’ = LDL-C + Lp(a)-C: implications of achieved ultra-low LDL-C levels in the proprotein convertase subtilisin/kexin type 9 era of potent LDL-C lowering. Curr Opin Lipidol 2015; 26:169–178.
Tsimikas S, Fazio S, Ferdinand KC, et al. NHLBI Working Group. Recommendations to reduce lipoprotein(a)-mediated risk of cardiovascular disease and aortic stenosis. J Am Coll Cardiol 2018; 71:177–192.
Trinder M, DeCastro ML, Azizi H, et al. Ascertainment bias in the association between elevated lipoprotein(a) and familial hypercholesterolemia. J Am Coll Cardiol 2020; 75:2682–2693.
Chan DC, Pang J, Hooper AJ, et al. Effect of lipoprotein(a) on the diagnosis of familial hypercholesterolemia: does it make a difference in the clinic? Clin Chem 2019; 65:1258–1266.
Ellis KL, Pang J, Chieng D, et al. Elevated lipoprotein(a) and familial hypercholesterolemia in the coronary care unit: between Scylla and Charybdis. Clin Cardiol 2018; 41:378–384.
Alonso R, Andres E, Mata N, et al. S. Investigators. Lipoprotein(a) levels in familial hypercholesterolemia: an important predictor of cardiovascular disease independent of the type of LDL receptor mutation. J Am Coll Cardiol 2014; 63:1982–1989.
Perez de Isla L, Alonso R, Mata N, et al. Predicting cardiovascular events in familial hypercholesterolemia: the SAFEHEART Registry (Spanish Familial Hypercholesterolemia Cohort Study). Circulation 2017; 135:2133–2144.
Chan DC, Pang J, Hooper AJ, et al. Elevated lipoprotein(a), hypertension and renal insufficiency as predictors of coronary artery disease in patients with genetically confirmed heterozygous familial hypercholesterolemia. Int J Cardiol 2015; 201:633–638.
Langsted A, Kamstrup PR, Benn M, et al. High lipoprotein(a) as a possible cause of clinical familial hypercholesterolaemia: a prospective cohort study. Lancet Diabetes Endocrinol 2016; 4:577–587.
Pavanello C, Pirazzi C, Bjorkman K, et al. Individuals with familial hypercholesterolemia and cardiovascular events have higher circulating Lp(a) levels. J Clin Lipidol 2019; 13:778–787. e6.
Sun D, Zhou BY, Zhao X, et al. Lipoprotein(a) level associates with coronary artery disease rather than carotid lesions in patients with familial hypercholesterolemia. J Clin Lab Anal 2018; 32:e22442.
Ten Kate GR, Bos S, Dedic A, et al. Increased aortic valve calcification in familial hypercholesterolemia: prevalence, extent, and associated risk factors. J Am Coll Cardiol 2015; 66:2687–2695.
Vongpromek R, Bos S, Ten Kate GJ, et al. Lipoprotein(a) levels are associated with aortic valve calcification in asymptomatic patients with familial hypercholesterolaemia. J Intern Med 2015; 278:166–173.
Santos RD, Raal FJ, Catapano AL, et al. Mipomersen, an antisense oligonucleotide to apolipoprotein B-100, reduces lipoprotein(a) in various populations with hypercholesterolemia: results of 4 phase III trials. Arterioscler Thromb Vasc Biol 2015; 35:689–699.
Ellis KL, Perez de Isla L, Alonso R, et al. Value of measuring lipoprotein(a) during cascade testing for familial hypercholesterolemia. J Am Coll Cardiol 2019; 73:1029–1039.
McCormick SPA, Schneider WJ. Lipoprotein(a) catabolism: a case of multiple receptors. Pathology 2019; 51:155–164.
Tsimikas S, Gordts P, Nora C, et al. Statin therapy increases lipoprotein(a) levels. Eur Heart J 2020; 41:2275–2284.
Lamina C, Kronenberg F, Lp GC. Estimation of the required lipoprotein(a)-lowering therapeutic effect size for reduction in coronary heart disease outcomes: a Mendelian randomization analysis. JAMA Cardiol 2019; 4:575–579.
Burgess S, Ference BA, Staley JR, et al. C. European Prospective Investigation Into, and C. Nutrition-cardiovascular disease, association of LPA variants with risk of coronary disease and the implications for lipoprotein(a)-lowering therapies: a Mendelian randomization analysis. JAMA Cardiol 2018; 3:619–627.
Bittner VA, Szarek M, Aylward PE, et al. O.O. Committees, and Investigators. Effect of alirocumab on lipoprotein(a) and cardiovascular risk after acute coronary syndrome. J Am Coll Cardiol 2020; 75:133–144.
O’Donoghue ML, Fazio S, Giugliano RP, et al. Lipoprotein(a), PCSK9 inhibition, and cardiovascular risk. Circulation 2019; 139:1483–1492.
Tsimikas S, Karwatowska-Prokopczuk E, Gouni-Berthold I, et al. A.K.-A.-L.S. Investigators. Lipoprotein(a) reduction in persons with cardiovascular disease. N Engl J Med 2020; 382:244–255.
Willeit P, Yeang C, Moriarty PM, et al. LDL-cholesterol corrected for Lp(a)-cholesterol, risk thresholds and cardiovascular events. JAHA under review 2020; In press.
Langsted A, Kamstrup PR, Nordestgaard BG. High lipoprotein(a) and high risk of mortality. Eur Heart J 2019; 40:2760–2770.